2. Academic Validation
  3. The latest perspectives of small molecules FMS kinase inhibitors

The latest perspectives of small molecules FMS kinase inhibitors

  • Eur J Med Chem. 2023 Dec 5:261:115796. doi: 10.1016/j.ejmech.2023.115796.
Bilal O Alkubaisi 1,  Raya Aljobowry 2,  Salma M Ali 2,  Sara Sultan 2,  Seyed-Omar Zaraei 1,  Anil Ravi 1,  Taleb H Al-Tel 3,  Mohammed I El-Gamal 4
Affiliations

Affiliations

  • 1 Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates.
  • 2 College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates.
  • 3 Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates; College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates. Electronic address: [email protected].
  • 4 Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates; College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates; Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. Electronic address: [email protected].
PMID: 37708796 DOI: 10.1016/j.ejmech.2023.115796
Abstract

FMS kinase is a type III tyrosine kinase receptor that plays a central role in the pathophysiology and management of several diseases, including a range of Cancer types, inflammatory disorders, neurodegenerative disorders, and bone disorders among Others. In this review, the pathophysiological pathways of FMS kinase in different diseases and the recent developments of its monoclonal antibodies and inhibitors during the last five years are discussed. The biological and biochemical features of these inhibitors, including binding interactions, structure-activity relationships (SAR), selectivity, and potencies are discussed. The focus of this article is on the compounds that are promising leads and undergoing advanced clinical investigations, as well as on those that received FDA approval. In this article, we attempt to classify the reviewed FMS inhibitors according to their core chemical structure including pyridine, pyrrolopyridine, pyrazolopyridine, quinoline, and pyrimidine derivatives.

Keywords

Anti-inflammatory; Anticancer; CSF-1R; FMS antibody; FMS inhibitor; Microglia.

Figures